147 related articles for article (PubMed ID: 27941880)
21. Mismatch repair pathway: molecules, functions, and role in colorectal carcinogenesis.
Sameer AS; Nissar S; Fatima K
Eur J Cancer Prev; 2014 Jul; 23(4):246-57. PubMed ID: 24614649
[TBL] [Abstract][Full Text] [Related]
22. The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells.
Bommi PV; Bowen CM; Reyes-Uribe L; Wu W; Katayama H; Rocha P; Parra ER; Francisco-Cruz A; Ozcan Z; Tosti E; Willis JA; Wu H; Taggart MW; Burks JK; Lynch PM; Edelmann W; Scheet PA; Wistuba II; Sinha KM; Hanash SM; Vilar E
Cancer Res; 2021 May; 81(10):2760-2773. PubMed ID: 34003775
[TBL] [Abstract][Full Text] [Related]
23. Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions.
Ruemmele P; Dietmaier W; Terracciano L; Tornillo L; Bataille F; Kaiser A; Wuensch PH; Heinmoeller E; Homayounfar K; Luettges J; Kloeppel G; Sessa F; Edmonston TB; Schneider-Stock R; Klinkhammer-Schalke M; Pauer A; Schick S; Hofstaedter F; Baumhoer D; Hartmann A
Am J Surg Pathol; 2009 May; 33(5):691-704. PubMed ID: 19252434
[TBL] [Abstract][Full Text] [Related]
24. Mismatch repair-deficient crypt foci in Lynch syndrome--molecular alterations and association with clinical parameters.
Staffa L; Echterdiek F; Nelius N; Benner A; Werft W; Lahrmann B; Grabe N; Schneider M; Tariverdian M; von Knebel Doeberitz M; Bläker H; Kloor M
PLoS One; 2015; 10(3):e0121980. PubMed ID: 25816162
[TBL] [Abstract][Full Text] [Related]
25. Pathways of colorectal carcinogenesis.
Arends MJ
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):97-102. PubMed ID: 23417071
[TBL] [Abstract][Full Text] [Related]
26. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
[TBL] [Abstract][Full Text] [Related]
27. An alternative pathway in colorectal carcinogenesis based on the mismatch repair system and p53 expression in Korean patients with sporadic colorectal cancer.
Kim HR; Kim HC; Yun HR; Kim SH; Park CK; Cho YB; Yun SH; Lee WY; Chun HK
Ann Surg Oncol; 2013 Nov; 20(12):4031-40. PubMed ID: 22732839
[TBL] [Abstract][Full Text] [Related]
28. Pitfalls in molecular analysis for mismatch repair deficiency in a family with biallelic pms2 germline mutations.
Leenen CH; Geurts-Giele WR; Dubbink HJ; Reddingius R; van den Ouweland AM; Tops CM; van de Klift HM; Kuipers EJ; van Leerdam ME; Dinjens WN; Wagner A
Clin Genet; 2011 Dec; 80(6):558-65. PubMed ID: 21204794
[TBL] [Abstract][Full Text] [Related]
29. EPCAM germline and somatic rearrangements in Lynch syndrome: identification of a novel 3'EPCAM deletion.
Spaepen M; Neven E; Sagaert X; De Hertogh G; Beert E; Wimmer K; Matthijs G; Legius E; Brems H
Genes Chromosomes Cancer; 2013 Sep; 52(9):845-54. PubMed ID: 23801599
[TBL] [Abstract][Full Text] [Related]
30. Susceptibility of Msh2-deficient mice to inflammation-associated colorectal tumors.
Kohonen-Corish MR; Daniel JJ; te Riele H; Buffinton GD; Dahlstrom JE
Cancer Res; 2002 Apr; 62(7):2092-7. PubMed ID: 11929830
[TBL] [Abstract][Full Text] [Related]
31. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
[TBL] [Abstract][Full Text] [Related]
32. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
Skeldon SC; Semotiuk K; Aronson M; Holter S; Gallinger S; Pollett A; Kuk C; van Rhijn B; Bostrom P; Cohen Z; Fleshner NE; Jewett MA; Hanna S; Shariat SF; Van Der Kwast TH; Evans A; Catto J; Bapat B; Zlotta AR
Eur Urol; 2013 Feb; 63(2):379-85. PubMed ID: 22883484
[TBL] [Abstract][Full Text] [Related]
33. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
[TBL] [Abstract][Full Text] [Related]
35. Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine.
Planck M; Ericson K; Piotrowska Z; Halvarsson B; Rambech E; Nilbert M
Cancer; 2003 Mar; 97(6):1551-7. PubMed ID: 12627520
[TBL] [Abstract][Full Text] [Related]
36. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
[TBL] [Abstract][Full Text] [Related]
37. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
[TBL] [Abstract][Full Text] [Related]
38. Associations of defect mismatch repair genes with prognosis and heredity in sporadic colorectal cancer.
Ghanipour L; Jirström K; Sundström M; Glimelius B; Birgisson H
Eur J Surg Oncol; 2017 Feb; 43(2):311-321. PubMed ID: 27836416
[TBL] [Abstract][Full Text] [Related]
39. Early-onset colorectal cancer is an easy and effective tool to identify retrospectively Lynch syndrome.
Perea J; Rodríguez Y; Rueda D; Marín JC; Díaz-Tasende J; Álvaro E; Alegre C; Osorio I; Colina F; Lomas M; Hidalgo M; Benítez J; Urioste M
Ann Surg Oncol; 2011 Nov; 18(12):3285-91. PubMed ID: 21590452
[TBL] [Abstract][Full Text] [Related]
40. Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2(loxP/loxP) Villin-Cre mice.
Kortüm B; Campregher C; Lang M; Khare V; Pinter M; Evstatiev R; Schmid G; Mittlböck M; Scharl T; Kucherlapati MH; Edelmann W; Gasche C
Gut; 2015 Dec; 64(12):1905-12. PubMed ID: 25429050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
